4. CAR-NK Cells: From Natural Basis to Designfor Kill. Front Immunol, 2021. 5. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer, 2022 6. Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in th...
CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach Xiaofei Zhang, Qin Hu, Xuesong He, Xinyue Cui, Zhaoyuan Liang, Li Wang, Xiongwei Deng, Ze Zhang, Wang Sheng & Xiaodong D. Han Journal of Nanob...
anti-PD1 antibody and CD16 CAR-T cells. A CpG ODN was encapsulated by CMG and PS to form CpG ODN –loaded nanoparticle (CNPs) through self-assembly approach. Vaccines were generated by mixing CNPs with tumor-derived antigens, such as TCL and neoantigens or the mixture of TCL and...
CD16-CARcetuximabPD-L1immunotherapyThe switchable CARs have shown many advantages in CAR T-cell therapy. However, human primary T cells are required to evaluate of antigen-specific adaptors by IFN-纬 assay or FACS analysis, which limits the throughput of adaptor screening. A sensitive and robust...
CD16-chimeric antigen receptors (CAR) T cells recognise the Fc-portion of therapeutic antibodies, which can enable the selective targeting of different antigens. Limited evidence exists as to which CD16-CAR design and antibody partner might be most effective. We have hypothesised that the use of...
PD-L1 t-haNK细胞是人类衍生的同种异体NK细胞系,经过工程设计以表达靶向PD-L1的嵌合抗原受体(CAR),其起源于NantKwest专有的NK-92(aNK)主细胞库。除了靶向PD-L1,PD-L1.t-haNK还被工程化表达CD16受体(V158 FcγRIIIa)的高...
CD16-CAR-T:靶向CD16+免疫细胞(临床前阶段)。 联合策略:CD16激动剂(如IL-15)联合双特异性抗体。 5. 总结与展望 (1)挑战 亚型特异性:需开发选择性靶向CD16A/B的药物; 动态调控:治疗中CD16表达下调导致的耐药机制。 (2)未来方向 纳米抗体:双价CD16激动剂增强免疫突触形成; 多组学整合:结合CD16多...
CD16-CAR-T:靶向CD16+免疫细胞(临床前阶段)。 联合策略:CD16激动剂(如IL-15)联合双特异性抗体。 5. 总结与展望 (1)挑战 亚型特异性:需开发选择性靶向CD16A/B的药物; 动态调控:治疗中CD16表达下调导致的耐药机制。 (2)未来方向 纳米抗体:双价CD16激动剂增强免疫突触形成; 多组学整合:结合CD16多...
PD-L1 t-haNK细胞是人类衍生的同种异体NK细胞系,经过工程设计以表达靶向PD-L1的嵌合抗原受体(CAR),其起源于NantKwest专有的NK-92(aNK)主细胞库。除了靶向PD-L1,PD-L1.t-haNK还被工程化表达CD16受体(V158 FcγRIIIa)的高亲和力变体,它通过附着在以前与癌细胞结合的单克隆抗体上,以介导抗体依赖性细胞毒性(...
随着嵌合抗原受体(CAR)修饰的T细胞(CAR-T)技术的兴起,NK细胞的CAR修饰潜力也受到了关注[13]。通过CAR修饰NK细胞有望增强其靶向杀伤肿瘤细胞的能力并研制出具有强大抗肿瘤作用的效应细胞。NK细胞治疗将为肿瘤的免疫治疗带来新的突破。 【相关文献】 [1]张雪花,王秀芬.NK细胞免疫治疗在恶性肿瘤治疗中的应用与护理[J...